Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Glucose Monitoring, Other

August 24, 2020

Bayer Commits ~$100M in One Drop Series C

Here is a brief preview of this blast: One Drop and Bayer announced an updated agreement for the joint development of digital health products in CV, oncology, and women’s health. As part of the agreement, Bayer has led One Drop’s $34.7M Series C funding round and has committed to an additional $64M in development fees and potential commercial milestone payments. Below, FENIX provides thoughts on how One Drop got this far with Bayer, if One Drop took a down round, and some potential irony with Bayer’s focus on diabetes.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.